Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Anderson on Future Treatment Landscape of Multiple Myeloma

Kenneth C. Anderson, MD
Published: Tuesday, Aug 30, 2016


Kenneth C. Anderson, MD, a 2014 Giant of Cancer Care in Myeloma, program director, Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics, institute physician, Dana-Farber Cancer Institute/Brigham and Women's Cancer Center, discusses how currently available agents will continue to impact the field of multiple myeloma.

Not one agent alone will be enough to make an impact on all patients, Anderson explains. This is especially true in events of disease recurrence, when the numbers of mutations significantly increase—and are usually not the same as they were in an initial myeloma case. Therefore, more agents need to be available in order to target various mutations.

Combination regimens will be a likely step for future treatment approaches, he says. PD-1/PD-L1 agents, though not approved in this setting, could have potential in this patient population.

Kenneth C. Anderson, MD, a 2014 Giant of Cancer Care in Myeloma, program director, Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics, institute physician, Dana-Farber Cancer Institute/Brigham and Women's Cancer Center, discusses how currently available agents will continue to impact the field of multiple myeloma.

Not one agent alone will be enough to make an impact on all patients, Anderson explains. This is especially true in events of disease recurrence, when the numbers of mutations significantly increase—and are usually not the same as they were in an initial myeloma case. Therefore, more agents need to be available in order to target various mutations.

Combination regimens will be a likely step for future treatment approaches, he says. PD-1/PD-L1 agents, though not approved in this setting, could have potential in this patient population.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™ Decision Points in Advanced NSCLC: Assessing Treatment Options Beyond Disease ProgressionNov 30, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x